Aimee Murphy

Vice President, Clinical Operations

Professional Overview
Aimee Murphy is an accomplished clinical operations executive with extensive experience leading high-impact initiatives in the biopharmaceutical industry. As the Vice President of Clinical Operations at Totus Medicines, she is responsible for overseeing all aspects of clinical study execution, from trial design and planning to site management and regulatory compliance. With a strong background in oncology drug development, Aimee has a proven track record of driving operational excellence and delivering transformative results for her organizations.

Experience Summary

Current Role
Aimee currently serves as the Vice President of Clinical Operations at Totus Medicines, a position she has held since May 2022. In this role, she is responsible for developing and implementing robust clinical strategies, optimizing operational processes, and ensuring the successful execution of the company's clinical trial portfolio. Aimee's leadership has been instrumental in accelerating the advancement of Totus Medicines' pipeline and enhancing the organization's clinical capabilities.

Career Progression
Prior to her current role, Aimee held several senior-level positions in the biopharmaceutical industry, including Executive Director of Clinical Operations Oncology at Gilead Sciences, Vice President of Development Operations at Forty Seven Inc., and Vice President of Clinical Operations & Development at Aduro Biotech, Inc. Throughout her career, Aimee has demonstrated a strong ability to navigate complex regulatory environments, foster cross-functional collaboration, and drive the successful advancement of promising drug candidates.

Academic Background
Aimee holds a Bachelor of Science degree in Biology from the University of California, Davis, and a Master of Business Administration from the University of San Francisco.

Areas of Expertise

• Clinical trial design, planning, and execution

• Oncology drug development

• Regulatory compliance and submission management

• Operational optimization and process improvement

• Cross-functional team leadership and collaboration

Professional Impact
During her tenure at Gilead Sciences, Aimee led the successful execution of several pivotal oncology trials, contributing to the advancement of the company's pipeline. At Forty Seven Inc., she played a pivotal role in the development and implementation of innovative clinical strategies, which ultimately led to the company's acquisition by Gilead Sciences. At Aduro Biotech, Aimee's strategic leadership and operational expertise were instrumental in driving the advancement of the company's novel immunotherapy programs.

Conclusion
Aimee Murphy is a seasoned clinical operations executive with a proven track record of driving operational excellence and delivering transformative results in the biopharmaceutical industry. Her deep expertise in oncology drug development, combined with her strong leadership skills and commitment to operational excellence, make her a valuable asset to Totus Medicines as the company continues to advance its innovative pipeline.